Business Wire

Publicis.Sapient and European DataWarehouse to Build Securitisation Repository for New Simple, Transparent and Standardized (STS) Regulation

Del

Publicis.Sapient the world’s most advanced digital transformation company, today announced it has been selected by the European DataWarehouse (ED) as its transformation partner to become the first securitisation repository under the new EU regulation for Simple, Transparent and Standardized (STS) securitisations, expected to take effect in 2019.

ED is the designated European repository for loan-level data stemming from Asset Backed Securities (ABS). It was established under European Central Bank's loan-level initiative in 2012. Publicis.Sapient has been the implementation partner of ED since the very beginning. Today more than 500 issuers, investors, central banks and other data users utilise ED’s data infrastructure.

The European Securities and Markets Authority (ESMA) is changing the regulatory framework for the securitisation market in the EU with the introduction of the STS regulation. Under STS, securitisations will be stimulated and mandatory transparency requirements introduced. Loan-level data, investor reports and other related documents must be submitted on a regular basis to an authorised repository. The repositories will then process, validate and store the securitisation related data and assess the data quality of submissions. Issuers, investors and regulators will be enabled to fulfil the STS due diligence requirements and supervise the EU securitisation market.

ED aims to become the first such securitisation repository that will serve regulators, originators, sponsors, investors and rating agencies under the new securitisation regulation. Publicis.Sapient will act as the transformation partner to build out the cloud-hosted platform that will act as a central data repository, providing a seamless experience to ED clients reporting under the European Central Bank requirements and the STS regulatory framework.

“We’re delighted that ED has selected Publicis.Sapient as its strategic transformation partner and that we can continue to help further its mission of delivering transparency in financial markets. By providing a unique, cloud-based platform, ED is creating a modern repository for banks, servicers and other market participants to support compliance with the new securitisation regulation,” said Bernd Harnisch, Vice President of Consulting at Publicis.Sapient.

“The usage of advanced front-end technologies to provide outstanding user experience for the clients of European DataWarehouse and a thorough understanding of the STS regulation are the foundation for designing this data repository. With agile project methodologies, we can rapidly react to regulatory changes and deliver tangible results on a continuous basis,” added Jens Schuback, Senior Manager and Project Lead at Publicis.Sapient.

“At the European DataWarehouse, we have been serving issuers and investors of Asset Backed Securities in the European Union for more than five years,” added Christian Thun, CEO, European DataWarehouse. “The transparency requirements under the new STS regulation will be a challenge for our clients as well as for us. Nonetheless, the European DataWarehouse is determined to become the first securitisation repository under the new STS framework in order to cater for the needs of the market.”

About Publicis.Sapient

Publicis.Sapient, the Digital Business Transformation hub of Publicis Groupe, is purpose-built to help businesses transform for the digital age, enabling seamless adaptation to a world where consumer behavior and technology disruption are catalyzing social and commercial change. With 19,000 people and 100 offices around the globe, our expertise spanning technology, data sciences, consulting and creative enables us to deliver on complex transformation initiatives that accelerate the evolution, growth and value for our clients’ businesses. For more information, visit www.publicis.sapient.com.

About European DataWarehouse (ED)

European DataWarehouse (ED) is the first and the only centralised data repository in Europe for collecting, validating and distributing detailed, standardised and asset class specific loan level data for Asset-Backed Securities (ABS) and private whole loan portfolios. ED stores loan-level data and corresponding documentation for investors and other market participants. Operating as a market infrastructure and designated by the Eurosystem, ED aims to increase transparency and restore confidence in the ABS market. Through ED’s data, users are able to analyse underlying portfolios in a more efficient way and compare portfolios on a systematic basis.

ED currently hosts data for more than 1250 public ABS transactions across Europe.

Contact information

Publicis.Sapient
Geoff Whitehouse, 44 (0) 207 456 6550
Head of PR
gwhitehouse@sapient.com
or
European DataWarehouse GmbH
Diane Wathen, 49 (0) 69 50986 9326
Marketing & Communications Manager
diane.wathen@eurodw.eu

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00Pressemelding

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10Pressemelding

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13Pressemelding

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00Pressemelding

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41Pressemelding

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00Pressemelding

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i